{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:06:23Z","timestamp":1763550383555,"version":"3.45.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-01038-3","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:29:00Z","timestamp":1763548140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multifaceted anticancer activity of nafamostat mesylate in human fibrosarcoma: first evidence of mitochondrial apoptosis and suppressed MMP-2\/-9 mRNA expression"],"prefix":"10.1186","volume":"26","author":[{"given":"Cafer","family":"Yildirim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiz","family":"Bakar-Ates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"61","key":"1038_CR1","doi-asserted-by":"publisher","first-page":"104638","DOI":"10.18632\/oncotarget.20136","volume":"8","author":"D Augsburger","year":"2017","unstructured":"Augsburger D, Nelson PJ, Kalinski T, Udelnow A, Kn\u00f6sel T, Hofstetter M, et al. Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies. Oncotarget. 2017;8(61):104638\u201353.","journal-title":"Oncotarget"},{"issue":"1","key":"1038_CR2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41392-021-00647-8","volume":"6","author":"V Damerell","year":"2021","unstructured":"Damerell V, Pepper MS, Prince S. Molecular mechanisms underpinning sarcomas and implications for current and future therapy. Signal Transduct Target Ther. 2021;6(1):246.","journal-title":"Signal Transduct Target Ther"},{"key":"1038_CR3","doi-asserted-by":"publisher","first-page":"1284428","DOI":"10.3389\/fcell.2023.1284428","volume":"11","author":"X Tang","year":"2023","unstructured":"Tang X, Hu X, Wen Y, Min L. Progressive insights into fibrosarcoma diagnosis and treatment: leveraging fusion genes for advancements. Front Cell Dev Biol. 2023;11:1284428.","journal-title":"Front Cell Dev Biol"},{"key":"1038_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000420222","volume":"93","author":"Y Ohtake","year":"1991","unstructured":"Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol. 1991;93:215\u20137.","journal-title":"Contrib Nephrol"},{"issue":"2","key":"1038_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-018-02567-w","volume":"109","author":"D Minakata","year":"2019","unstructured":"Minakata D, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, et al. Comparison of gabexate mesilate and Nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019;109(2):141\u201346.","journal-title":"Int J Hematol"},{"issue":"2","key":"1038_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4266\/acc.2021.01312","volume":"37","author":"JH Lee","year":"2022","unstructured":"Lee JH, Park JH, Jang JH, Kim SH, Hong SY, Heo W, et al. The role of Nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation. Acute Crit Care. 2022;37(2):177\u201384.","journal-title":"Acute Crit Care"},{"issue":"2","key":"1038_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/nano.202100123","volume":"3","author":"BF Niemeyer","year":"2022","unstructured":"Niemeyer BF, Miller CM, Ledesma-Feliciano C, Morrison JH, Jimenez-Valdes R, Clifton C, et al. Broad antiviral and anti-inflammatory efficacy of Nafamostat against SARS-CoV-2 and seasonal coronaviruses in primary human bronchiolar epithelia. Nano Sel. 2022;3(2):437\u201349.","journal-title":"Nano Sel"},{"key":"1038_CR8","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3389\/fonc.2019.00852","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Xu Z, Zeng S, Wang X, Liu W, Qian L, et al. The molecular aspect of antitumor effects of protease inhibitor Nafamostat mesylate and its role in potential clinical applications. Front Oncol. 2019;9:852.","journal-title":"Front Oncol"},{"issue":"20","key":"1038_CR9","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.3390\/jcm12206618","volume":"12","author":"TM Seccia","year":"2023","unstructured":"Seccia TM, Shagjaa T, Morpurgo M, Caroccia B, Sanga V, Faoro S, et al. Randomized clinical trial of Nafamostat Mesylate, A potent transmembrane protease Serine 2 (TMPRSS2) Inhibitor, in patients with COVID-19 pneumonia. J Clin Med. 2023;12(20):6618.","journal-title":"J Clin Med"},{"issue":"sup1","key":"1038_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/14756366.2016.1161620","volume":"31","author":"A Jab\u0142o\u0144ska-Trypu\u0107","year":"2016","unstructured":"Jab\u0142o\u0144ska-Trypu\u0107 A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31(sup1):177\u201383.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"8","key":"1038_CR11","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/s12276-023-01046-5","volume":"55","author":"TT Nguyen","year":"2023","unstructured":"Nguyen TT, Wei S, Nguyen TH, Jo Y, Zhang Y, Park W, et al. Mitochondria-associated programmed cell death as a therapeutic target for age-related disease. Exp Mol Med. 2023;55(8):1595\u2013619.","journal-title":"Exp Mol Med"},{"issue":"10","key":"1038_CR12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40262-022-01170-x","volume":"61","author":"MP Hern\u00e1ndez-Mitre","year":"2022","unstructured":"Hern\u00e1ndez-Mitre MP, Tong SYC, Denholm JT, Dore GJ, Bowen AC, Lewin SR, et al. Nafamostat mesylate for treatment of COVID-19 in hospitalised patients: A Structured, narrative review. Clin Pharmacokinet. 2022;61(10):1331\u201343.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1038_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7883\/yoken.JJID.2023.315","volume":"77","author":"M Wei","year":"2024","unstructured":"Wei M, Li T, Liu S, Wang Y, Tran C, Ao G. The effectiveness and safety of Nafamostat mesylate in the treatment of COVID-19: a Meta-Analysis. Jpn J Infect Dis. 2024;77(3):182\u201386.","journal-title":"Jpn J Infect Dis"},{"issue":"1","key":"1038_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.canlet.2016.06.014","volume":"380","author":"YX Lu","year":"2016","unstructured":"Lu YX, Ju HQ, Wang F, Chen LZ, Wu QN, Sheng H, Mo HY, Pan ZZ, Xie D, Kang TB, Chen G, Yun JP, Zeng ZL, Xu RH. Inhibition of the NF-\u03baB pathway by Nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Lett. 2016;380(1):87\u201397.","journal-title":"Cancer Lett"},{"issue":"9","key":"1038_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mc.20652","volume":"49","author":"ML Lin","year":"2010","unstructured":"Lin ML, Lu YC, Chung JG, Wang SG, Lin HT, Kang SE, Tang CH, Ko JL, Chen SS. Down-regulation of MMP-2 through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin leads to Inhibition of nasopharyngeal carcinoma cell invasion. Mol Carcinog. 2010;49(9):783\u201397.","journal-title":"Mol Carcinog"},{"issue":"2","key":"1038_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3892\/or.2017.5362","volume":"37","author":"C Guarneri","year":"2017","unstructured":"Guarneri C, Bevelacqua V, Polesel J, Falzone L, Cannav\u00f2 PS, Spandidos DA, Malaponte G, Libra M. NF-\u03baB Inhibition is associated with OPN\/MMP-9 downregulation in cutaneous melanoma. Oncol Rep. 2017;37(2):737\u201346.","journal-title":"Oncol Rep"},{"issue":"14","key":"1038_CR17","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/cancers13143466","volume":"13","author":"I Belhabib","year":"2021","unstructured":"Belhabib I, Zaghdoudi S, Lac C, Bousquet C, Jean C. Extracellular matrices and cancer-Associated fibroblasts: targets for cancer diagnosis and therapy? cancers. (Basel). 2021;13(14):3466.","journal-title":"(Basel)"},{"key":"1038_CR18","doi-asserted-by":"publisher","first-page":"105138","DOI":"10.1016\/j.tiv.2021.105138","volume":"73","author":"M Ergul","year":"2021","unstructured":"Ergul M, Bakar-Ates F. Investigation of molecular mechanisms underlying the antiproliferative effects of Colchicine against PC3 prostate cancer cells. Toxicol Vitro. 2021;73:105138.","journal-title":"Toxicol Vitro"},{"issue":"4","key":"1038_CR19","doi-asserted-by":"publisher","first-page":"e20191533","DOI":"10.1590\/0001-3765202020191533","volume":"92","author":"AS Cinar","year":"2020","unstructured":"Cinar AS, Bakar-Ates F, Onder A. Seseli petraeum M. Bieb. (Apiaceae) significantly inhibited cellular growth of A549 lung cancer cells through G0\/G1 cell cycle arrest. Acad Bras Cienc. 2020;92(4):e20191533.","journal-title":"Acad Bras Cienc"},{"issue":"4","key":"1038_CR20","doi-asserted-by":"publisher","first-page":"e20200548","DOI":"10.1590\/0001-3765202020200548","volume":"92","author":"E Ozkan","year":"2020","unstructured":"Ozkan E, Bakar-Ates F. Potentiation of the effect of Lonidamine by Quercetin in MCF-7 human breast cancer cells through downregulation of MMP-2\/9 mRNA expression. Acad Bras Cienc. 2020;92(4):e20200548.","journal-title":"Acad Bras Cienc"},{"issue":"1","key":"1038_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/his.12282","volume":"64","author":"AL Folpe","year":"2014","unstructured":"Folpe AL. Fibrosarcoma: a review and update. Histopathology. 2014;64(1):12\u201325.","journal-title":"Histopathology"},{"issue":"1","key":"1038_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin WL. Drug repurposing for cancer therapy. Signal Transduct Target Ther. 2024;9(1):92.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1038_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1254\/jjp.41.155","volume":"41","author":"M Iwaki","year":"1986","unstructured":"Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, et al. Pharmacological studies of FUT-175, Nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41(2):155\u201362.","journal-title":"Jpn J Pharmacol"},{"issue":"3","key":"1038_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/039139888801100316","volume":"11","author":"M Hiraishi","year":"1988","unstructured":"Hiraishi M, Yamazaki Z, Ichikawa K, Kanai F, Idezuki Y, Onishi K, et al. Plasma collection using Nafamostat mesilate and dipyridamole as an anticoagulant. Int J Artif Organs. 1988;11(3):212\u20136.","journal-title":"Int J Artif Organs"},{"issue":"3","key":"1038_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00535-019-01644-z","volume":"55","author":"M Hirota","year":"2020","unstructured":"Hirota M, Shimosegawa T, Kitamura K, Takeda K, Takeyama Y, Mayumi T, et al. Continuous regional arterial infusion versus intravenous administration of the protease inhibitor Nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial. J Gastroenterol. 2020;55(3):342\u201352.","journal-title":"J Gastroenterol"},{"issue":"1","key":"1038_CR26","doi-asserted-by":"publisher","first-page":"101302","DOI":"10.1016\/j.tranon.2021.101302","volume":"15","author":"YT Lin","year":"2022","unstructured":"Lin YT, Lin J, Liu YE, Hsu KW, Hsieh CC, Chen DR, et al. Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression. Transl Oncol. 2022;15(1):101302.","journal-title":"Transl Oncol"},{"issue":"4","key":"1038_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3892\/or.2010.843","volume":"24","author":"K Furukawa","year":"2010","unstructured":"Furukawa K, Iida T, Shiba H, Fujiwara Y, Uwagawa T, Shimada Y, et al. Anti-tumor effect by Inhibition of NF-\u03baB activation using Nafamostat mesilate for pancreatic cancer in a mouse model. Oncol Rep. 2010;24(4):843\u201350.","journal-title":"Oncol Rep"},{"issue":"8","key":"1038_CR28","first-page":"3173","volume":"29","author":"T Uwagawa","year":"2009","unstructured":"Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K. Combination chemotherapy of Nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res. 2009;29(8):3173\u20138.","journal-title":"Anticancer Res"},{"issue":"23","key":"1038_CR29","doi-asserted-by":"publisher","first-page":"12827","DOI":"10.3390\/ijms222312827","volume":"22","author":"M Ghasemi","year":"2021","unstructured":"Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT assay: Utility, Limitations, Pitfalls, and interpretation in bulk and Single-Cell analysis. Int J Mol Sci. 2021;22(23):12827.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1038_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3892\/mco.2022.2571","volume":"17","author":"M Morimoto","year":"2022","unstructured":"Morimoto M, Toyoda H, Niwa K, Hanaki R, Okuda T, Nakato D, et al. Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor Inhibition. Mol Clin Oncol. 2022;17(3):138.","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"1038_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12272-017-0996-9","volume":"41","author":"S Mander","year":"2018","unstructured":"Mander S, You DJ, Park S, Kim DH, Yong HJ, Kim DS, et al. Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells. Arch Pharm Res. 2018;41(2):229\u201342.","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1038_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2013.01.019","volume":"333","author":"T Gocho","year":"2013","unstructured":"Gocho T, Uwagawa T, Furukawa K, Haruki K, Fujiwara Y, Iwase R, et al. Combination chemotherapy of Serine protease inhibitor Nafamostat mesilate with oxaliplatin targeting NF-\u03baB activation for pancreatic cancer. Cancer Lett. 2013;333(1):89\u201395.","journal-title":"Cancer Lett"},{"issue":"22","key":"1038_CR33","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3390\/cells13221838","volume":"13","author":"M Mustafa","year":"2024","unstructured":"Mustafa M, Ahmad R, Tantry IQ, Ahmad W, Siddiqui S, Alam M, et al. Apoptosis: A comprehensive overview of signaling Pathways, morphological Changes, and physiological significance and therapeutic implications. Cells. 2024;13(22):1838.","journal-title":"Cells"},{"issue":"1","key":"1038_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, et al. NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9(1):53.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1038_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2131\/jts.49.467","volume":"49","author":"J Xu","year":"2024","unstructured":"Xu J, Chen J, Wang D, Li Y, Lian P, Wu X, et al. Nafamostat mesylate sensitizes ovarian cancer cells to carboplatin by promoting the ZNF24-mediated Inhibition of WNT2B. J Toxicol Sci. 2024;49(11):467\u201379.","journal-title":"J Toxicol Sci"},{"issue":"1","key":"1038_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.canlet.2016.06.014","volume":"380","author":"YX Lu","year":"2016","unstructured":"Lu YX, Ju HQ, Wang F, Chen LZ, Wu QN, Sheng H, et al. Inhibition of the NF-\u03baB pathway by Nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Lett. 2016;380(1):87\u201397.","journal-title":"Cancer Lett"},{"key":"1038_CR37","doi-asserted-by":"publisher","first-page":"111272","DOI":"10.1016\/j.cellsig.2024.111272","volume":"121","author":"S Kumari","year":"2024","unstructured":"Kumari S, Singh P, Singh R. Repeated silica exposures lead to silicosis severity via PINK1\/PARKIN mediated mitochondrial dysfunction in mice model. Cell Signal. 2024;121:111272.","journal-title":"Cell Signal"},{"issue":"2","key":"1038_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/targets2020007","volume":"2","author":"A Shoari","year":"2024","unstructured":"Shoari A. Potential of MMP-2 and MMP-9 gelatinase Blockade as a therapeutic strategy in fibrosarcoma treatment: A decadal review. Targets. 2024;2(2):104\u201325.","journal-title":"Targets"},{"key":"1038_CR39","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3389\/fonc.2019.01370","volume":"9","author":"S Quintero-Fabi\u00e1n","year":"2019","unstructured":"Quintero-Fabi\u00e1n S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Arg\u00e1ez V, Lara-Riegos J, et al. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol. 2019;9:1370.","journal-title":"Front Oncol"},{"issue":"1","key":"1038_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/biom15010035","volume":"15","author":"A Shoari","year":"2025","unstructured":"Shoari A, Ashja Ardalan A, Dimesa AM, Coban MA. Targeting invasion: the role of MMP-2 and MMP-9 Inhibition in colorectal cancer therapy. Biomolecules. 2025;15(1):35.","journal-title":"Biomolecules"},{"issue":"4","key":"1038_CR41","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.anl.2006.12.002","volume":"34","author":"Y Yamashita","year":"2007","unstructured":"Yamashita Y, Ishiguro Y, Sano D, Kimura M, Fujita K, Yoshida T, et al. Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma. Auris Nasus Larynx. 2007;34(4):487\u201391.","journal-title":"Auris Nasus Larynx"},{"key":"1038_CR42","doi-asserted-by":"crossref","unstructured":"Sugano H, Shirai Y, Horiuchi T, Saito N, Shimada Y, Eto K, et al. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers (Basel). 2018;10(10):386. Erratum in: Cancers (Basel). 2019;11(3):335.","DOI":"10.3390\/cancers11030335"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01038-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:03:15Z","timestamp":1763550195000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-01038-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01038-3","relation":{},"ISSN":["2050-6511"],"issn-type":[{"type":"electronic","value":"2050-6511"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}